Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)AMANDA OLGA MÜLLER, Roger von Moos, AJ Templeton et al.|Cancer Research|2019Cited by 2
Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular CorrelationsIlaria Romano, Davide Rossi, Saemi Schaer et al.|Blood|2024Cited by 0